Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

SEPTEMBER 20, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children. About Virpax Pharmaceuticals. Christopher M. Chipman, CPA. Betsy Brod.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

NOVEMBER 15, 2021

–(BUSINESS WIRE)– #earnings — Virpax ® Pharmaceuticals, Inc. Finally, we recently acquired the worldwide rights to VRP324, which is an intranasal pharmaceutical-grade cannabidiol product candidate for the management of epilepsy in children (rare pediatric disease) and adults. RECENT DEVELOPMENTS.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug. ” About The Study.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Epilepsy Behav. Accessed July 25, 2021.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

MARCH 2, 2020

Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. This renewed interest in psychedelics is being sparked by a pair of seemingly unrelated events. Then, something strange happened. In 2018, the U.S.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

The Joint Blog

FEBRUARY 15, 2020

According to a new study published in the journal Epilepsy & Behavior, abruptly stopping the use of CBD (cannabidiol) is not associated with physical withdrawal symptoms. Researchers reported no serious adverse events resulting from the discontinuation of CBD. Thirty volunteers were randomized to receive 750?mg Conclusion.

CBD 54

CBD Treatment Events Epilepsy 54

Cannabis Law Report

DECEMBER 8, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Single-dose transdermal delivery of Epoladerm was well-tolerated in all minipigs and no treatment-related clinical observations, changes in body weight, or dermal irritation were observed. About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

MARCH 6, 2020

” In 2018, Europe was responsible for 23.2% of the world’s pharmaceutical sales with the size of the market in the EU-5 ( United Kingdom , Germany , Spain , France , and Italy ) set to grow by 25% between 2017 and 2022. This is the sixth patent grant that Kannalife has received. About KLS-13019. Medical Marijuana, Inc.

Research and Development 59

Research and Development Marijuana Pharmaceutical Supply Chain 59

Veriheal

JULY 28, 2021

However, the leadership council of the North Carolina-based Eastern Band of Cherokee Indians made serious headway in May, when the council agreed to legalize small amounts of pharmaceutical-grade cannabis for use on tribal territory. Overview of the Medical Cannabis Bill.

Seed-To-Sale 59

Seed-To-Sale Research and Development Pharmaceutical Conditions 59

The Joint Blog

JANUARY 10, 2022

Hence, CBD is an enticing choice for those looking for pain relief and treatments that lack the mind-altering impact of cannabis or the additional adverse effects associated with some pharmaceutical medicines. Symptoms include: Reliving traumatic events. However, unlike THC, CBD lacks psychoactive effects. Schizophrenia.

CBD 41

CBD Sleep Treatment Epilepsy 41

Cannabis Law Report

OCTOBER 6, 2021

With the additional funding recently secured by Virpax and the strengthening of our balance sheet, we are continuing to advance our product candidates and to move them through preclinical studies and into human clinical trials,” said Anthony Mack, Chairman and Chief Executive Officer of Virpax Pharmaceuticals. About Virpax Pharmaceuticals.

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

NOVEMBER 5, 2019

You might feel anxious before a meeting, an examination, or a big event. The first thing to note on this subject matter is there is isn’t a large body of research on anxiety treatment using CBD oil. At least not as much we have with regards to epilepsy treatment. Anxiety is a daily occurrence for most of us.

Oil 58

Oil CBD Digestion Epilepsy 58

Cannabis Law Report

JUNE 1, 2021

Prior to UroGen, Mr. Barbera held various leadership roles at Dendreon Pharmaceuticals, Allergan, and Medimmune, among others. About Vicineum™ Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate being developed for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Veriheal

SEPTEMBER 22, 2021

As per the proposed bill, multiple sclerosis (MS), Parkinson’s disease , epilepsy , post-traumatic stress disorder (PTSD), and HIV/AIDS are some examples of medical conditions featured on the list of qualifying criteria. Home cannabis cultivation, on the other hand, would be forbidden. by 2024.

Legalization 111

Legalization Patients Cultivation Legislation 111

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Knowing these can allow you or your healthcare provider to look up the metabolism of a pharmaceutical drug and determine if a CBD-drug interaction is possible. Medicines 6.1

CBD 98

CBD THC Conditions Medicine 98

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. Knowing these can allow you or your healthcare provider to look up the metabolism of a pharmaceutical drug and determine if a CBD-drug interaction is possible. 2014): 86-95. [2]

CBD 52

CBD THC Conditions Medicine 52

Cannabis Law Report

JANUARY 20, 2022

Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K.

Therapy 52

Therapy Research and Development Business Access 52

The Cannigma

MAY 7, 2021

In Europe, Murphy explains, cannabis products are held to the same standards of accountability and repeatability as other pharmaceuticals. What do those more pharmaceutical standards mean for patients? You have over, I think in our last event, we had 10,000 meetings take place. SM: I think it’s stability.

Supply Chain 120

Supply Chain Patients Access Hemp 120

Canna Law Blog

NOVEMBER 16, 2021

In the event a Tribe or State doesn’t develop a plan or the plan is rejected by USDA, then growers will just follow the overall system put together by USDA (these directives are very similar to the standards set out in the 2018 Farm Bill, legalizing hemp). ” SBA fairness. ” SBA fairness. International law and treaties.

DEA 88

DEA Business Banking Food 88

Cannabis Law Report

NOVEMBER 24, 2021

Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ). Refractory paediatric epilepsy. Conclusions.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

OCTOBER 26, 2019

doctors) for patients who are ‘seriously ill with a condition from which death is reasonably likely to occur within a matter of months, or from which premature death is reasonably likely to occur in the absence of early treatment’ Category B is an application pathway that can be accessed by health practitioners (e.g.,

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

JULY 15, 2022

The schedule eight pharmaceutical medicine has gained federal approval to treat conditions including cancer-related pain, nausea and vomiting, multiple sclerosis and epilepsy, and for use in palliative care. But bottlenecks remain to doctors prescribing the controversial treatment. Media event date: 27 August 2019.

Medicine 52

Medicine Patients Media Supply Chain 52

Green Relief

MAY 13, 2018

It is the most commonly identified cause of epilepsy among adults. Treatment modalities for TBI are limited with few satisfactory pharmaceutical options available. Triggered by concussions from car accidents, falls, violent contact sports, explosives or by gunshot and stab wounds, TBI affects 1.7 million Americans annually.

THC 64

THC CBD Cannabinoids Research and Development 64

The Cannigma

DECEMBER 22, 2021

We have autism and epilepsy. I think anyone that gets into this business is, we get addicted to this, to the smart event where we’re working around the clock, there’s always something new. Because it’s not in the list and the doctors wants to give the prescription. It’s quite a large operation.

Research and Development 79

Research and Development Oil Cannabis Clinical Trials 79

Green Relief

MAY 12, 2018

It is the most commonly identified cause of epilepsy among adults. Treatment modalities for TBI are limited with few satisfactory pharmaceutical options available. Triggered by concussions from car accidents, falls, violent contact sports, explosives or by gunshot and stab wounds, TBI affects 1.7 million Americans annually.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40

Cannabis Law Report

OCTOBER 17, 2019

Many experts believe it can lead to beneficial treatments, reiterated in a report released by the National Academies of Sciences, Engineering, and Medicine in January 2017. They don’t want to disallow access to the only thing that may stop epileptic seizures in children or is part of a patient’s treatment plan.”

Law 40

Law Seed-To-Sale Hemp Recreational 40